Latest Derivatives News

Osteopore Limited has landed a two-year distribution deal for an innovative autologous dentin graft technology in Singapore, setting the stage for expansion across ASEAN and the wider Asia-Pacific dental market.

Bio-Gene Technology Limited reports strong progress in toxicology studies for Flavocide, targeting its first regulatory submission in Australia by March 2027. This milestone sets the stage for global registrations of the novel insecticide with a new mode of action.

Astron Limited has released updated Mineral Resource and Ore Reserve estimates for its Donald Project, highlighting increased production forecasts for critical heavy rare earth elements. The project remains shovel ready, backed by comprehensive feasibility studies and regulatory approvals.

Excelsior Capital Limited reported a $2.08 million loss for the half-year ending December 2025 as it moves to wind up operations, yet declared a substantial fully franked interim dividend.

Investigator Silver Limited’s Definitive Feasibility Study confirms the Paris Silver Project as a high-margin, low-risk development with rapid payback and modest funding needs. The study outlines a conventional open-pit mine in South Australia, poised for near-term production with robust financial metrics.

4DMedical Limited’s half-year report reveals rapid commercial traction following FDA clearance of its CT:VQ™ imaging technology, alongside a $150 million institutional placement that bolsters its cash reserves for global expansion.

Harvest Technology Group’s half-year report reveals a 50% revenue decline and a widening net loss, offset by a $6 million funding facility and strategic partnerships.

Cynata Therapeutics reported a reduced half-year loss alongside progress in pivotal clinical trials, extending its cash runway into mid-2026. Investors await critical data from Phase 3 and Phase 2 studies expected in the coming months.

Change Financial has reported a strong first half for FY26 with record revenue growth and its first-ever half-year profit, underpinned by expanding recurring revenues and operational efficiencies.

TPC Consolidated Limited reported a 4.1% revenue increase to $103.6 million and a 62% jump in underlying EBITDA for the half-year ended December 2025, while the proposed acquisition scheme faces regulatory hurdles.

Imricor Medical Systems saw a sharp 69.5% decline in revenue for 2025, driven by clinical trial impacts, yet narrowed its net loss to $25.3 million as it secured FDA clearance for key products post-year-end.

Tetratherix Limited reported a $4.6 million statutory loss for the first half of FY26, driven by increased R&D and manufacturing investments, while making significant progress in clinical trials and securing key global partnerships.